NCT06538116

A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease

A Randomized, Double-Blinded Study to Evaluate the Efficacy and Safety of Mevidalen in Patients With Alzheimer's Disease

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 300 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 50 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease (AD) dementia. This is done by looking at participants: thinking and memory (cognition), everyday activities and sleep, AD symptoms, physical activity, irritability or anxiety. The study is expected to last approximately 26 weeks and may include up to 14 visits.

Conditions

• Alzheimer Disease

Interventions

Type	Name	Description
DRUG	Mevidalen	Administered orally
DRUG	Placebo	Administered orally

Timeline

• Start date: 2024-08-26
• Primary completion: 2026-05-01
• Completion: 2026-05-01
• First posted: 2024-08-05
• Last updated: 2025-12-17

Locations

64 sites across 2 countries: United States, Japan

Regulatory

• FDA-regulated drug study